Aiforia Technologies

3.92EUR +0.51 %
916 investors are following this company

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.

P/E (23e)
-8.47
EV/EBIT (adj.) (23e)
-8.05
P/B (23e)
6.08
Dividend yield-% (23e)
-
Target price
4.50 EUR
Recommendation
Reduce
Updated
28.8.2023
First North Finland
AIFORIA
Daily low / high price
3.89 / 3.93 EUR
Market cap
101.71M EUR
Turnover
1.32K EUR
Volume
336
Risk and recommendation
HighRiskLow
SellRecommendationBuy

Major Owners
Source: Millistream Market Data AB

OwnerCapitalVotes
Sto-Rahoitus Oy5.8 %5.8 %
Johan Lundin5.5 %5.5 %
Premium
Not activated

This content is for our Premium customers only.

Insider Transactions

InsiderDateTotal value
Johan Lundin22.06.2023495,750EUR
Jukka Tapaninen30.12.20224,043.861EUR
Premium
Not activated

This content is for our Premium customers only.

Forum updates

Stay up-to-date with the latest talk about Aiforia Technologies

Income statement

20192020202120222023e2024e2025e2026e
Revenue0.640.850.971.872.745.5711.7219.72
growth-%134.93 %32.86 %14.72 %91.79 %46.47 %103.54 %110.46 %68.27 %
EBITDA-2.14-1.61-3.45-8.11-8.89-7.26-3.471.05
EBIT (adj.)-3.02-2.63-4.69-10.20-12.06-12.38-9.76-6.30
EBIT-3.02-2.63-4.69-10.20-12.06-12.38-9.76-6.30
Profit before taxes-3.05-2.76-7.58-10.61-12.25-12.58-10.06-6.60
Net income-3.05-2.76-7.58-10.61-12.25-12.58-10.06-6.60
EPS (adj.)-0.15-0.14-0.29-0.41-0.46-0.44-0.30-0.19
growth-%
Dividend0.000.000.000.000.000.000.000.00
Dividend ratio

Profitability and return on capital

20192020202120222023e2024e2025e2026e
EBITDA-%-335.05 %-189.75 %-354.21 %-434.10 %-324.80 %-130.32 %-29.65 %5.34 %
EBIT-% (adj.)-472.93 %-310.13 %-481.42 %-546.20 %-440.96 %-222.29 %-83.28 %-31.94 %
EBIT-%-472.93 %-310.13 %-481.42 %-546.20 %-440.96 %-222.29 %-83.28 %-31.94 %
ROE-147.62 %-386.27 %-39.11 %-31.60 %-52.87 %-113.02 %-777.74 %111.24 %
ROI-78.85 %-77.00 %-20.92 %-28.06 %-44.14 %-66.45 %-76.16 %-58.32 %

Valuation

20192020202120222023e2024e2025e2026e
Share price (EUR)5.223.233.923.923.923.92
Shares19.9719.9725.7825.8326.4528.5133.0034.32
Market cap134.5783.42103.68111.76129.35134.55
Enterprise value99.3761.4197.16118.00143.05154.32
EV/S--102.0232.8835.5121.1912.217.82
EV/EBITDA-------146.40
EV/EBIT (adj.)--------
EV/EBIT--------
P/E (adj.)--------
P/E--------
P/B--3.562.856.0821.41--
P/S--138.1644.6637.9020.0711.046.82
Dividend yield
Equity ratio12.77 %16.82 %86.28 %82.88 %65.02 %26.74 %-14.43 %-46.73 %
Gearing ratio127.73 %146.05 %-93.00 %-75.15 %-38.29 %119.67 %-520.12 %-214.16 %

Quarter data

Q3/22Q4/222022Q1/23Q2/23Q3/23eQ4/23e2023eQ1/24e
Revenue1.141.870.921.822.74
EBITDA-4.60-8.11-4.88-4.14-8.89
EBIT-5.81-10.20-6.18-5.88-12.06
Profit before taxes-6.23-10.61-6.25-5.99-12.25
Net income-6.23-10.61-6.25-5.99-12.25
Publisher
Aiforia: The journey won't be a straight line

Aiforia continues its successes on the customer front, but H1 revenue was well below our expectations. We see clear opportunities for the company to be one of the winners in its market in the long term. The downside to the potential is the low predictability of the growth rate also seen in H1 and the clearly elevated financial risks. At a rising valuation level, we believe that the compensation for these risks over a 12-month period is too thin.

Research28.08.2023 by Antti Luiro, Frans-Mikael Rostedt